Paracetamol pills urgently recalled over contamination fears
A statement issued by the Medicines and Healthcare products Regulatory Agency (MHRA) said Chelonia Healthcare Limited is recalling specific batches of Paracetamol 500mg Tablets (100 pots)
An urgent recall has been issued for batches of paracetamol which could be contaminated
(Image: Anton Petrus via Getty Images )
Patients have been urged to return certain batches of paracetamol due to contamination fears, according to an announcement made on Monday. The Medicines and Healthcare products Regulatory Agency (MHRA) said that Chelonia Healthcare Limited, the manufacturer, is recalling specific batches of paracetamol 500mg tablets (100 pots) as a precautionary measure, reports the Mirror.
The urgent recall is reportedly "due to contamination following a small number of complaints of discoloured tablets within the pots" and an alert has been issued to anyone who has bought them.
It advises: "Patients or carers should check to see if they have received tablets from the listed batches of Paracetamol 500 mg Tablets. The batch number can be found on the label of the medicine bottle and on the outer carton.
"These tablets can only be obtained from a pharmacy with a prescription. The number of tablets you will have been given will vary depending on your prescription and you may have only received a small number of tablets." For the latest restaurant news and reviews, sign up to our food and drink newsletter here .
Medicine Details:
Paracetamol 500mg Tablets.
Article continues below
PL: 33414/0126.
Active ingredient: Paracetamol.
SNOMED code: 33554711000001108.
GTIN: 05060014445506.
The statement further added: "The tablets should be 'white capsule-shaped tablets, scored on one side', as per the Patient Information Leaflet (PIL). If you find tablets that are discoloured in any way, in pots from the listed batches, please contact your pharmacist or the healthcare professional who dispensed your prescription.
"Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme."
Article continues below
The MHRA has classified the recall as Class 2, suggesting that while the defect could result in mistreatment or harm, it is not deemed life-threatening or serious.
Pharmacists have been given explicit instructions: "Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier, using your supplier's approved process."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
21 hours ago
- Daily Mail
Health officials were warned of rogue Botox beauticians a YEAR ago - but failed to act
Drug safety chiefs were warned last year about rogue beauty therapists injecting illegal Botox-style products but failed to act before the jabs hospitalised dozens. The procedures, carried out by beauticians using unlicensed versions of botulinum toxin, left 38 people across the North East, North West, East of England and Midlands seriously ill with paralysis-like symptoms and breathing difficulties. The alarming outbreak this month has exposed 'gaping holes' in regulation, claim senior doctors now calling on the Government to ban medically unqualified practitioners from administering cosmetic injections. Dr Steven Land, a Newcastle-based expert in aesthetic medicine, said he first raised concerns in November 2023 with the Medicines and Healthcare products Regulatory Agency (MHRA). 'Our only surprise is that this didn't happen sooner,' he said. 'I was getting WhatsApp messages and emails every week from people selling knock-off toxin – illegal, unlicensed products that you can buy online with no checks.' Dr Land said he provided the MHRA with names, phone numbers, pricing information and screenshots of practitioners openly advertising cut-price anti-wrinkle jabs using unlicensed botulinum toxin. He added: 'When I followed up in April, they told me the matter would be dealt with 'in due course'. Nothing happened. If action had been taken when I raised the alarm, dozens might not have ended up in hospital.' MHRA was asked to comment. Due to the severity of the situation, the UK Health Security Agency (UKHSA) announced this month it had launched an inquiry. The practitioners involved are said to be cooperating, although no further detail has been given. Dr Land said two beauty therapists operating in his area had been identified as the primary source of the outbreak. Both had used a Korean-manufactured product called Toxpia. 'Neither had any medical qualifications – just basic beauty therapy training – and both were injecting clients in salons and private homes using the same unlicensed product,' he said. 'We believe they were buying this toxin online and administering it with no clinical oversight.' HJ Corporations Co. Ltd, the maker of Toxpia, was approached for comment. More than seven million people in the UK undergo cosmetic treatments – including Botox and fillers – each year and demand is growing. The industry is now worth an estimated £3.6billion. Yet in Britain, anyone can legally offer cosmetic injections regardless of medical training – a situation many doctors have long condemned. A recent study by University College London found that two in three procedures are carried out by non-medics, including hairdressers and beauty therapists. Dr Christopher Rowland Payne, president of the Royal Society of Medicine Section of Aesthetic Medicine and Surgery, said: 'The current situation is quite terrifying. It is irresponsible for the Government to allow this to continue. 'Britain is the odd man out in Europe in allowing non-medics to perform these procedures.' Dr Rowland Payne, who gave evidence to the women and equalities committee on the issue, also highlighted the stark differences in training between medics and non-medics offering Botox. Botulinum toxin – the active ingredient in Botox – is one of the most powerful poisons known, being found in soil and contaminated food. When consumed, it can cause botulism – a potentially fatal illness that leads to muscle paralysis and respiratory failure. Its potency is staggering: gram-for-gram, botulinum toxin is estimated to be 100,000 times more toxic than cyanide. Experts stress that the risk is not with approved brands – such as Botox, Dysport, Xeomin and Jeuveau – but with counterfeit or unlicensed versions used by untrained individuals. Toxpia is not licensed for use in the UK though industry insiders say it is available to buy online. In 2023, the Government launched a consultation on new rules for the aesthetics sector and Health Secretary Wes Streeting suggested this month a crackdown was imminent. Kaylie Bailey, 36, from Peterlee, County Durham, was left fighting for her life and now wears an eye patch after developing paralysis and losing the ability to breathe. She had paid £75 for cut-price anti-wrinkle jabs from beautician Gemma Gray – who has since admitted the product caused widespread harm but claimed it was a 'nationwide problem'. 'I remember lying on the bed thinking 'I'm dying',' added Ms Bailey, who spent three days in intensive care with botulism. We're having to live with what she [the beautician] did to us. I nearly died because of it.'
The Sun
3 days ago
- The Sun
Urgent recall for asthma medication taken by thousands as health chiefs warn of wrong dose instruction
AN urgent warning has been issued for a common inhaler used by asthma sufferers due to a mistake on the labelling. The error affecting Flutiform 250 micrograms inhalers means asthma patients could be informed of the wrong dose of the drug. 1 In its alert, UK medicines regulator, the MHRA said: "CD Pharma Ltd [the inhaler's manufacturer] have notified the MHRA of an error on the outer carton of the product for the batches listed in this notification. "While the total active content statement is correct, the delivered dose content statement is incorrect." The other product details on the inhaler carton, however, including the name, strength and pharmaceutical form of the medicine, are correct. And the quality of the medicine has not been impacted by the labelling defect. Patients have been advised to continue to take the medication as prescribed by their healthcare professionals. Meanwhile, healthcare professionals have been advised to stop supplying the above batch immediately. The recall urged: "Quarantine all stock and return it to your supplier using your supplier's approved process." "This is a wholesale and pharmacy level recall that will be actioned by a healthcare professional," added the MHRA. "There is no quality issue with the product and patients can continue to take their medicine as prescribed." The labelling mistake means patients may have thought they were only receiving half the necessary dose of the medication. Early Warning Signs of an Asthma Attack As part of the recall, patients who do experience adverse reactions or have any questions about the medication are advised to seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card Scheme. Asthma is a common condition. In the UK, 7.2 million people have asthma. This is about eight in every 100 people, according to Asthma + Lung UK. It affects the airways that carry air in and out of your lungs, causing them to become inflamed. This makes the airways narrower so less air gets into and out of the lungs. Symptoms, like wheezing, breathlessness, a cough or a tight chest, can be triggered by things like exercise, allergens or changes in weather. At the moment there is no cure for asthma, but most people with asthma can control their symptoms well with asthma inhalers. Depending on how severe your symptoms are, the NHS says you may be offered either: an inhaler to use only when you get symptoms – this is called an anti-inflammatory reliever (AIR) inhaler an inhaler to use every day to help prevent symptoms, as well as when you get symptoms – this is called a maintenance and reliever therapy (MART) inhaler two separate inhalers – a preventer inhaler to use every day to help prevent symptoms, and a blue reliever inhaler to use when you get symptoms (you should not be given a blue reliever inhaler to use on its own) The NHS also advises: "It's important to use your inhaler correctly so that your medicine works properly. "There are different types, including dry powder inhalers, pMDIs and soft mist inhalers.
Daily Mail
3 days ago
- Daily Mail
Health chiefs issue urgent recall for asthma medication prescribed to thousands
An urgent recall has been issued for a common inhaler used by people with severe asthma. The UK medicines regulator, the MHRA, have said that the Flutiform 250 micrograms inhaler is to be returned to pharmacies. A mistake on the labelling means that patients could be informed of the wrong dose of the drug. Patients have been advised to continue to take the medicine as advised by their doctor and not to return or stop taking the product. In a statement on the MHRA website they said: 'This is a wholesale and pharmacy level recall that will be actioned by a healthcare professional. There is no quality issue with the product and patients can continue to take their medicine as prescribed.' The watchdog was notified by the manufacturer CD pharma limited of the issue. They said: 'an error on the outer carton of the product for the batches listed in this notification. While the total active content statement is correct, the delivered dose content statement is incorrect. The other details on the carton are correct.' The mistake means that patients may have thought that they were only receiving half the necessary dose of the medication. The respiratory condition asthma affects around 7.2million people in the UK, and asthma attacks kill, on average, three people in Britain every day. It affects the airways, or breathing tubes, that carry air in and out of the lungs, causing them to become inflamed. This makes the airways narrower so less air gets into and out of the lungs. Symptoms include wheezing, breathlessness, a cough or a tight chest — and are often triggered by factors in the environment like pollution, stress or a cold. Inhalers work to control the disease by reducing the number of blood cells that contribute to the lung inflammation.
